Tag Archives: Drogenil
New Prostate Cancer Agent Improves Survival by Nearly 5 Months!
Excellent news for prostate cancer patients whose cancer has progressed after hormonal treatment and chemotherapy! An experimental oral agent, MDV3100 (Medivation) was found to improve survival in metastatic castration-resistant prostate cancer by 4.8 months The new agent, called MDV3100, is … Continue reading →
Posted in Cancer, Prostate cancer
|
Tagged abiraterone, AFFIRM, bicalutamide, cabazitaxel, Casodex, docetaxel, Drogenil, flutamide, Jevtana, MDV3100, Medivation, metastatic castration-resistant prostate, Prostate cancer, Provenge, sipuleucel-T, Survival, Taxotere, Zytiga
|
Comments Off on New Prostate Cancer Agent Improves Survival by Nearly 5 Months!